Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeReportar como inadecuado

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Cardiovascular Diabetology

, 4:6

First Online: 15 May 2005Received: 10 March 2005Accepted: 15 May 2005


BackgroundMetabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-gamma PPARγ activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome.

MethodsIn a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan 80 mg, n = 20 or losartan 50 mg, n = 20 for 3 months. At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin HBA1c and 24-hour mean systolic and diastolic blood pressures were determined.

ResultsTelmisartan, but not losartan, significantly p < 0.05 reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic. Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan. Telmisartan also significantly reduced 24-hour mean systolic blood pressure p < 0.05 and diastolic blood pressure p < 0.05 compared with losartan.

ConclusionAs well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARγ activity.

Keywordsangiotensin II receptor blockers telmisartan losartan hypertension metabolic syndrome Electronic supplementary materialThe online version of this article doi:10.1186-1475-2840-4-6 contains supplementary material, which is available to authorized users.

Cristiana Vitale, Giuseppe Mercuro, Carlotta Castiglioni, Alessandra Cornoldi, Arianna Tulli, Massimo Fini, Maurizio Volterrani and Giuseppe MC Rosano contributed equally to this work.

Download fulltext PDF

Autor: Cristiana Vitale - Giuseppe Mercuro - Carlotta Castiglioni - Alessandra Cornoldi - Arianna Tulli - Massimo Fini - Maurizio 


Documentos relacionados